All articles tagged with #ldl c reduction
Merck announced promising Phase 3 trial results showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% with a safety profile similar to placebo, potentially offering a new oral treatment for cardiovascular disease prevention.
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, potentially making it the first oral PCSK9 inhibitor if approved.
Merck announced positive topline results from two Phase 3 trials of enlicitide decanoate, an oral PCSK9 inhibitor, showing significant LDL-C reductions in adults with hyperlipidemia, with no major safety concerns, potentially making it the first oral PCSK9 inhibitor if approved.
Older adults may experience a greater reduction in low-density lipoprotein cholesterol (LDL-C) when treated with low- to moderate-intensity statin therapy compared to younger patients, according to a study. The research analyzed data from over 83,000 adults in Denmark and found that older patients had a higher percentage reduction in LDL-C compared to younger patients when taking simvastatin or atorvastatin. The study suggests that low- to moderate-intensity statin therapy may be more beneficial for older adults at increased risk for adverse events. However, the results should be interpreted with caution due to limitations in the study population and lack of information about body mass index.